ĐÁNH GIÁ CHỈ SỐ PALBI TRONG TIÊN LƯỢNG BỆNH NHÂN UNG THƯ BIỂU MÔ TẾ BÀO GAN NGUYÊN PHÁT

Abstract

Objective: Evaluate the PALBI index in the prognosis of patients with primary hepatocellular carcinoma. Research subjects and methods: Retrospective descriptive study on 83 patients diagnosed with primary hepatocellular carcinoma with ICD code C22 according to the standards of the Ministry of Health in 2012 treated at Nghe An General Friendship Hospital from January 2017 to July 2021. Results: The proportion of patients with PALBI 1,2,3 was 61.4, 32.5 and 6%. At 12 months, survival rates according to PALBI groups 1,2,3 were 96.1, 77.8, and 20%. The survival rate gradually decreased in the increasing PALBI groups; this difference was statistically significant with p < 0.001. At 24 months, survival rates according to PALBI group 1,2,3 were 76.5, 37.0 and 0%. The survival rate gradually decreased in the increasing PALBI groups; this difference was statistically significant with P<0.001. The average overall survival time according to PALBI groups 1,2,3 is 31.4, 21.6, and 9.5 months, respectively. The difference is statistically significant with p < 0.001. Conclusion: The PALBI index can predict relatively good survival time in patients with BMT. Applying this scale to stratify patients with cervical cancer instead of the child-pugh scale will bring many benefits in clinical practice.